Evidence map›Paper›PMID 40675108›Full record

ArticleVaccine2025

MIP3α-Rel

James T Gordy, Jean J Zheng, Amanda R Maxwell, Rowan E Bates, Alannah D Taylor, Styliani Karanika, Heemee Ton, Jacob Meza, Yangchen Li, Jiaqi Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

James T GordyW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. Electronic address: Jgordy2@jhu.edu.
Jean J ZhengW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Amanda R MaxwellDepartment of Molecular and Comparative Pathobiology, Research Animal Resources, Johns Hopkins University, Baltimore, MD, United States.
Rowan E BatesW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Alannah D TaylorW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Styliani KaranikaTuberculosis Research Advancement Center, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Heemee TonW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Jacob MezaW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Yangchen LiW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Jiaqi ZhangW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Petros C KarakousisW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Tuberculosis Research Advancement Center, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: petros@jhmi.edu.
Richard B MarkhamW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. Electronic address: rmarkha1@jhu.edu.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Pharmacology and Pharmacometrics CoreP30AI168436 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson, Petros C Karakousis · 2022 to 2026
$6.1M
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persistersR01AI148710 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C, MARKHAM, RICHARD B. · 2020 to 2024
$3.8M
Mentoring in Immunometabolic Dysregulation in TB and TB/HIVK24AI143447 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2019 to 2024
$956k
Mechanisms of a therapeutic DNA vaccine targeting Mycobacterium tuberculosis persistersK08AI174959 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Styliani Karanika · 2024 to 2026
$603k
NIAID NIH HHS K08 AI174959NIAID NIH HHS K24 AI143447NIAID NIH HHS P30 AI094189NIAID NIH HHS P30 AI168436NIAID NIH HHS R01 AI148710
6 · The paper itself

Abstract

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is the leading cause of mortality due to a single infectious organism. While generally curable, TB requires a lengthy and complex antibiotic regimen, due in large part to persistent bacteria that survive antibiotic exposure. Rel

Indexed as

Chemokine CCL20LungT-LymphocytesTuberculosis VaccinesVaccines, DNAAdministration, IntranasalAnimalsDisease Models, AnimalFemaleMacaca mulattaMiceMycobacterium tuberculosisTuberculosisVaccinationChemokine CCL20Tuberculosis VaccinesVaccines, DNABronchoalveolar lavage fluidDNA vaccinesIntranasal immunizationLung T cell responsesMouse modelsMycobacterium tuberculosisNonhuman primatesPMA and ionomycin stimulationrhesus macaqueTherapeutic vaccines

Identifiers

PMID40675108
PMCPMC12313244

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.